0001415889-21-005966.txt : 20211215 0001415889-21-005966.hdr.sgml : 20211215 20211215183208 ACCESSION NUMBER: 0001415889-21-005966 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211213 FILED AS OF DATE: 20211215 DATE AS OF CHANGE: 20211215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CAPEK JOHN M CENTRAL INDEX KEY: 0001328034 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 211495358 MAIL ADDRESS: STREET 1: 111 MONUMENT CIRCLE, SUITE 2900 CITY: INDIANAPOLIS STATE: IN ZIP: 46204-5129 FORMER NAME: FORMER CONFORMED NAME: Capek John M DATE OF NAME CHANGE: 20050523 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 4 1 form4-12152021_031259.xml X0306 4 2021-12-13 0000001800 ABBOTT LABORATORIES ABT 0001328034 CAPEK JOHN M 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064 false true false false EXECUTIVE VICE PRESIDENT Common shares without par value 2021-12-13 4 M 0 149600 34.94 A 470998 D Common shares without par value 2021-12-13 4 S 0 149600 135.0515 D 321398 D Option (right to buy) 34.94 2021-12-13 4 M 0 149600 0 D 2016-02-15 2023-02-14 Common Shares 149600 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.295 inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c). /s/ John M. Capek by Jessica H. Paik, Attorney-in-Fact 2021-12-15